BioSpace News Archive

A newly published Random Clinical Trial (RCT) provides additional support for statements Xlear made about the use of nasal hygiene as an added layer of protection in combatting the SARS-CoV-2 virus.

Apollo Endosurgery, Inc. announced that the endoscopic sleeve gastroplasty procedure was featured in a 2022 Top 10 Paper at the International Federation for the Surgery of Obesity and Metabolic Disorders 2022 World Congress, held August 23-27 in Miami.

Aesther Healthcare Acquisition Corp (NASDAQ; AEHA) (“Aesther”), a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, or similar business combination with one or more businesses, today announced that it has entered into an Agreement and Plan of Merger with Ocean Biomedical, Inc. (“Ocean Biomedical”), a next-generation biopharma company, (the “Merger Agreement”).

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citi’s 17th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA.

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), announced today that the U.S. Food & Drug Administration (FDA) has granted tentative approval for Libervant™ (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.

Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced today that Stan Jacot, president and CEO and Pam Haley, CFO, will be participating in two investor conferences during the month of September.

Rallybio Corporation (Nasdaq: RLYB), today announced that company management will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:10 p.m. ET in Everett, MA.

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer of Abata will participate in the following investor conferences.